Who We Are
Our R&D, Management, and Regulatory Team
From a humanitarian mission to a scalable GI drug-development platform.
Our team has broken through long-standing barriers in GI drug development, advancing a highly effective therapy for a historically untreatable condition from concept through the highest-risk stages of development in humans, while earning recognition and support from WHO/GTFCC and the European Innovation Council for its significant humanitarian potential.
The same R&D team has now built a broader pipeline of potential therapies targeting major GI-driven conditions, including obesity, insulin resistance, inflammatory bowel disease, bloating, SIBO, and IBS-D.
2.1 Vision & Mission
Vision
EL 924 is designed to creat effective alternative that addresses key limitations of Incretine Based therapies (GLP-1/GIP) like adherence challenges, reliance on appetite suppression, lean mass loss, GI adverse effects and high cost allowing to better address obesity and insulin resistance epidemic on population level
Mission
2.3 Our Team
Our Core R&D, Management, and Regulatory Team
Our scientific experience was shaped by work conducted at leading academic institutions, including Yale and Vanderbilt, and further advanced through our independent R&D programs.
Our journey outside these institutions began with a humanitarian quest: to address one of the deadliest and most difficult challenges in gastrointestinal drug development that remained untreatable beyond supportive therapy— creating a true game-changing, targeted, disease-modifying therapy for secretory diarrhea and cholera..
Despite decades of effort, traditional approaches for drug development have fallen short due to significant and not trivial scientific barriers.
Our goal was to create a true game changer in secretory diarrhea suited also for developing countries where disease takes it biggest toll. In this setting, simply having an effective drug is not enough: the therapy must be oral, safe, practical, affordable, easy to use, temperature- and environment-stable, and easy to manufacture to truly make a difference. This created a dual challenge: solving the biology and making the therapy deployable in the real world.
Our R&D, management, and regulatory team successfully advanced this first-in-class program from concept through Phase II human clinical testing, demonstrating significant efficacy and a favorable safety profile. The program has been recognized as a potential high-humanitarian-impact project, including engagement with the WHO Global Task Force on Cholera Control and support from the European Innovation Council / Horizon program for Phase III development.
Following this success and lesson learned — and guided by our strong belief that real-world impact requires more than biological efficacy alone — our core R&D team developed a broader gut-directed drug-development platform.
This platform now supports programs across a wide range of GI-driven diseases, including obesity, insulin resistance, inflammatory bowel disease, functional GI disorders, and metabolic disease.
Elaphron was founded to promote this therapies
Core R&D, Management, Regulatory team
Dmitry Kravtsov
Adel Egri
Igor Rojkovskiy
Emilio Restoy